Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

INDIV 1

Study Type

Interventional 1

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 72Burkitt Lymphoma 43Neoplasm, Residual 18Leukemia 15Recurrence 14Lymphoma, Non-Hodgkin 8Leukemia, Biphenotypic, Acute 8Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoproliferative Disorders 6Lymphatic Diseases 5Lymphoma, Large B-Cell, Diffuse 4Lymphoma, B-Cell 4Lymphoma 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Leukemia, Lymphoid 4Immunoproliferative Disorders 4Neoplasms 3Blast Crisis 3Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Juvenile 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Myeloid 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hematologic Neoplasms 2Down Syndrome 2Bites and Stings 2Sarcoma, Myeloid 1Philadelphia-Negative ALL 1Philadelphia Chromosome 1

Interventions

rozanolixizumab 10zilucoplan 8efgartigimod alfa 8Rituximab 7Cyclophosphamide 7telitacicept 6fludarabine 6eculizumab 5Prednisone 5ravulizumab 4Pyridostigmine Bromide 4Immunoglobulins, Intravenous 4Hizentra 4Tacrolimus 3Mycophenolic Acid 3HBM9161 3Amifampridine 3thymoglobulin 2inebilizumab 2Prednisolone 2Exercise 2tofacitinib 1tocilizumab 1talquetamab 1satralizumab 1sargramostim 1rhoA GTP-Binding Protein 1remibrutinib 1prednylidene 1iscalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Myasthenia Gravis × blinatumomab × Clear all
NCT06836973 2025-03-25

Blinatumomab for Treatment of Refractory Myasthenia Gravis

Da, Yuwei, M.D.

Phase 2/3 Not yet recruiting
2 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡